Ovarian Cancer | Tumor

CURE’s ovarian cancer page is a go-to resource for oncology news and updates in the world of ovarian cancer Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in ovarian cancer.

Combination of Mirvetuximab Soravtansine and Avastin Demonstrates Effective Outcomes in Recurrent Ovarian Cancer

June 15th 2020

The combination of mirvetuximab soravtansine and Avastin (bevacizumab) demonstrated encouraging overall response rates in patients with ovarian cancer, regardless of the disease’s previous responsiveness to platinum-based chemotherapy, according to data presented at the 2020 ASCO Virtual Scientific Program.

Lynparza-Cediranib Combination Produces Similar Activity to Standard of Care Chemotherapy in Ovarian Cancer

June 11th 2020

The presentation of the complete data from the NRG-GY004 trial comes just months after AstraZeneca and Merck announced in a press release that the combination failed to meet its primary endpoint of progression-free survival.

CURE's Top Stories: May 2020

June 2nd 2020

Each month, we take a look back at the most popular CURE® stories. Here are the top five stories for May 2020.

Finding Meaning While Waiting in the Infusion Chair

May 23rd 2020

One survivor makes the most of the time in the infusion chair, creating beaded jewelry and helping herself and others to heal.

Teal on Wheels: Riding to Raise Ovarian Cancer Awareness

May 21st 2020

In this episode of the “CURE Talks Cancer” podcast, we spoke with a cervical cancer survivor - who is currently living with ovarian cancer - about a cross-country journey she took last summer on a teal and white Harley Davidson motorcycle to raise ovarian cancer awareness.

What You Need to Know About the FDA's Approval of Lynparza and Avastin for Advanced Ovarian Cancer

May 21st 2020

The Food and Drug Administration recently approved the combination of Lynparza (olaparib) and Avastin (bevacizumab) for patients with advanced ovarian cancer that carries a specific mutation and has responded to previous treatment with platinum-based chemotherapy plus Avastin. Here’s what you need to know.

FDA's Approval of Zejula Offers Patients with High-Grade Ovarian Cancer a Maintenance Therapy Option

May 20th 2020

The Food and Drug Administration’s recent approval of Zejula is different from previous approvals as it is indicated for all patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer, according to a gynecologic oncology expert.

Lynparza Maintenance Therapy Improves Survival in Relapsed, BRCA-Positive Ovarian Cancer

May 14th 2020

Treatment with Lynparza in the maintenance setting extended overall survival by more than a year in women with platinum-sensitive relapsed ovarian cancer with BRCA1/2 mutations.

FDA Approves Combination of Lynparza and Avastin as Maintenance Treatment for Advanced Ovarian Cancer

May 8th 2020

Lynparza and Avastin are now approved for patients with advanced ovarian cancer that carries a specific mutation and has responded to previous treatment with platinum-based chemotherapy plus Avastin.

Ovarian Cancer

May 6th 2020

Understanding ovarian cancer.

FDA Approves Zejula For Maintenance Treatment in Advanced Epithelial Ovarian Cancer

April 29th 2020

The Food and Drug Administration has approved the use of Zejula as a frontline maintenance treatment for adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who responded to chemotherapy.

A Patient with Ovarian Cancer Weathers the COVID-19 Storm at Her Local Health Center

April 16th 2020

The COVID-19 pandemic has changed how people receive health care services. For Donna Wiegle, director of the Mill Pond Health Center in Maine, and cervical cancer survivor and patient with ovarian cancer, the pandemic hasn’t yet changed how her island’s health center provides residents with routine care.

Living with Peace of Mind As a Two-Time Cancer Survivor

April 14th 2020

A two-time survivor shares how taking action led her doctors to catch an aggressive second cancer.

Phase 3 Trial Fails to Improve Progression-Free Survival in Previously Untreated Epithelial Ovarian Cancer

April 13th 2020

After failing to meet its primary endpoint of progression-free survival, the JAVELIN Ovarian PARP 100 clinical trial was stopped.

Refine and Retry, Getting Ovarian Cancer Treatment Right for Patients

April 10th 2020

CURE®’s Editor-in-Chief weighs in on how the treatment and detection landscape needs to be refined to help patients with ovarian cancer.

Genetic Testing: Are Over-the-Counter Options Reliable?

April 9th 2020

An expert raises her concerns about direct-to-consumer testing and shares ways people can protect themselves.

Breastfeeding Lowers the Risk of Ovarian Cancer

April 8th 2020

Regardless of breastfeeding duration, women who did so after giving birth had a lower risk of developing ovarian cancer, including high-grade tumors.

Managing Ovarian Cancer Recurrence

April 6th 2020

Women with ovarian cancer are living longer than ever, even those whose disease returns after initial treatment.

Survey Reveals Women Will Bear Side Effects, if a Drug Might Lengthen Life

April 4th 2020

PARP inhibitors show promise in lengthening the life of women with breast cancer, and they're willing to bear the side effects of the treatment.

How PARP Inhibitors Work In Women

April 2nd 2020

These targeted therapies fight disease by stopping the fix-it process in damaged cancer cells.

Understanding Risks for Breast Implant-Associated Lymphoma

February 20th 2020

Genetic Mutations in Men

February 20th 2020

Laws and Legislation Protecting Those with a Genetic Predisposition

February 20th 2020

Talking About Direct-To-Consumer Genetic Testing

February 20th 2020

PARP Inhibitors Will Likely Expand Treatment Options for Those Who Have Ovarian Cancer

February 18th 2020

PARP Inhibitors are opening new doors in cancer treatment by targeting vulnerabilities in cancer that researchers are beginning to understand better.

An Expanding Role For PARP Inhibitors Shows Promise In Treating Ovarian Cancer

February 14th 2020

PARP inhibitors interfere with cancer’s ability to repair damage to its DNA. They are becoming increasingly useful in treating ovarian cancer.

Unique Genetic Change Found in Rare Ovarian Tumor Could Spare Patients from Unnecessary Treatment

February 5th 2020

Investigators are studying a rare ovarian tumor called sclerosing stromal tumor, a benign tumor that can be misdiagnosed as cancer.

CURE's Top Stories: January 2020

February 2nd 2020

Take a look back at the top five CURE® stories for January 2020.

Friday Frontline: Cancer Updates, Research and Education on January 31, 2020

January 31st 2020

From NFL Hall of Famer Kurt Warner leading a recognition service for cancer caregivers during the Super Bowl to Tylenol’s key ingredient possibly being added to California’s proposition 65 list for chemicals that may cause cancer, here’s what is making headlines in the cancer space this week.

A Tale of Two Misdiagnoses

January 23rd 2020

In this week’s episode, a pair who is forever connected by their genetic risk for cancer talked about the revelations that came from a study they participated in that changed both of their lives.